Early estimates of updated 2023–2024 (monovalent XBB.1.5) COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection attributable to co-circulating Omicron variants among immunocompetent adults — increasing community access to testing program, United States, September 2023–January 2024 (면역력 있는 성인을 대상으로 하는 코로나바이러스 감염증(Omicron 변이)에 대한 2023–2024년 업데이트된 단일형 XBB.1.5 COVID-19 백신의 초기 추정 효과)
U.S. Department of Health and Human Services, Centers for Disease Control and Prevention2024-02-01
Early estimates of updated 2023–2024 (monovalent XBB.1.5) COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection attributable to co-circulating Omicron variants among immunocompetent adults — increasing community access to testing program, United States, September 2023–January 2024
(
면역력 있는 성인을 대상으로 하는 코로나바이러스 감염증(Omicron 변이)에 대한 2023–2024년 업데이트된 단일형 XBB.1.5 COVID-19 백신의 초기 추정 효과
)
